Exelixis
EXEL
$22.87
Share price
0.22%
Change (1 day)
15.80%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Number of shares outstanding for Exelixis (EXEL)
Number of shares outstanding as of April 2024 : 308,482,000
According to Exelixis's latest financial reports and stock price the company's current number of shares outstanding is 308,482,000. At the end of 2023 the company had 308,482,000 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Exelixis from 2001 to 2023
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2023 | 0.30 B | -4.57% |
| 2022 | 0.32 B | 1.79% |
| 2021 | 0.31 B | 2.19% |
| 2020 | 0.31 B | 2.11% |
| 2019 | 0.30 B | 1.65% |
| 2018 | 0.29 B | 1.14% |
| 2017 | 0.29 B | 2.73% |
| 2016 | 0.28 B | 26.69% |
| 2015 | 0.22 B | 16.32% |
| 2014 | 0.19 B | 6.05% |
| 2013 | 0.18 B | 10.83% |
| 2012 | 0.16 B | 28.81% |
| 2011 | 0.12 B | 18.84% |
| 2010 | 0.10 B | 1.24% |
| 2009 | 0.10 B | 1.69% |
| 2008 | 0.10 B | 7.1% |
| 2007 | 98.55 M | 17.07% |
| 2006 | 84.17 M | 5.83% |
| 2005 | 79.54 M | 10.21% |
| 2004 | 72.17 M | 1.66% |
| 2003 | 70.99 M | 25.69% |
| 2002 | 56.48 M | 18.29% |
| 2001 | 47.75 M |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 2,407,200,000 | 680.34% | 🇺🇸 USA |
 Pfizer PFE | 5,647,000,000 | 1,730.58% | 🇺🇸 USA |
 Amgen AMGN | 535,000,000 | 73.43% | 🇺🇸 USA |
 Sanofi SNY | 2,507,200,000 | 712.75% | 🇫🇷 France |
 Merck MRK | 2,554,166,667 | 727.98% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2,057,000,000 | 566.81% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2,028,000,000 | 557.41% | 🇬🇧 UK |
 Curis CRIS | 5,720,789 | -98.15% | 🇺🇸 USA |
 AVEO Oncology
AVEO | 34,618,000 | -88.78% | 🇺🇸 USA |